Angiopoietin-Tie2 and Multi-Kinase Receptor Tyrosine Kinase Network (Tie2/VEGFR/PDGFR/KIT Axis)

The Angiopoietin-Tie2 and Multi-Kinase Receptor Tyrosine Kinase Network is a comprehensive signaling axis that plays a pivotal role in tumor angiogenesis, oncogenesis, and the maintenance of the tumor microenvironment (NCI, 2024; Mross et al., 2012). This target profile includes the Tie2 receptor (TEK), which is regulated by Angiopoietin-1 and 2 to control vascular maturation and stability, as well as the Vascular Endothelial Growth Factor Receptors (VEGFR1, 2, and 3) that are primary drivers of endothelial cell proliferation (NCI, 2024; Targeted Oncology, 2014). Furthermore, the network incorporates Platelet-Derived Growth Factor Receptors (PDGFR) and the KIT proto-oncogene, which facilitate the recruitment of perivascular cells and direct tumor cell survival, respectively (NCI, 2024; PMC, 2023). By simultaneously inhibiting these diverse pathways, therapeutic agents can disrupt the redundant signaling mechanisms that tumors often use to escape single-target therapies (Targeted Oncology, 2014; AACR Journals, 2017). Drugs such as regorafenib are specifically designed to target this multi-kinase profile, demonstrating clinical efficacy in refractory solid tumors including metastatic colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (NCI, 2024; PMC, 2023). The inhibition of this network leads to a profound reduction in tumor vascularization and a significant increase in tumor cell apoptosis (Mross et al., 2012; MedChemExpress, 2024).

Other names

Angiogenic and oncogenic multi-kinase profileTie2-VEGFR-PDGFR-KIT signaling axisRegorafenib target profileMulti-kinase receptor tyrosine kinase network

Simultaneous competitive inhibition of the adenosine triphosphate (ATP) binding site within the intracellular kinase domains of multiple receptor tyrosine kinases (RTKs), leading to the suppression of downstream signaling cascades such as MAPK/ERK and PI3K/Akt that drive tumor growth and vascularization (Wilhelm et al., 2011; NCI, 2024).